RNA vs TECH · rev $10.9M vs P/E 65, rev $1.22B
Atrium Therapeutics, Inc. Common Stock (RNA) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported RNA revenue for 2024-12-31 was $10.9M. Net income was -$322.3M. Revenue was up 14.0% from 2023-12-31 to 2024-12-31. RNA currently screens at market cap $217.5M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
RNA currently screens at market cap $217.5M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the RNA and TECH stock pages for the full models.
Not investment advice.